Ronan Farrow’s recent exposé on Elon Musk highlights concerns about the prominent entrepreneur’s alleged influence over the U.S. government and his escalating ketamine usage. Farrow reports that both Musk’s companies, SpaceX and Tesla, have received preferential treatment from the Department of Defense and regulatory bodies. This lack of oversight raises alarm considering the significant impact Musk’s empire has in the fields of space technology and electric vehicles.
Earlier reports had already discussed Musk’s use of ketamine as a treatment for depression and at social gatherings. However, Farrow’s investigation suggests that Musk’s use of the drug has escalated in recent years, leading to concerns among associates. The isolation Musk experiences and his strained relationship with the media may amplify the effects of ketamine, potentially contributing to his impulsive statements and decisions.
Amit Anand, a leading ketamine researcher, explains that the drug can cause disinhibition, similar to alcohol, leading individuals to engage in unpredictable and impulsive behavior. The extent of the impact depends on the nature of the person’s work. For instance, a librarian faces less risk compared to a pilot, where the consequences could be severe.
In addition to concerns about Musk’s behavior, Farrow reveals that Musk has the power to disrupt the Ukrainian army’s communications through his satellite network, Starlink, operated by SpaceX. Musk even threatened to revoke Ukraine’s access after personally speaking with Vladimir Putin, as disclosed to defense officials. The details of the agreement between Musk and the Pentagon regarding Starlink’s use by Ukraine have not been disclosed.
The implications of Musk’s supposed control over government entities and his alleged increasing drug usage raise questions about the boundaries of his influence. It remains to be seen how this information will impact public perception of Musk and his companies, as well as calls for increased oversight.
Sources:
– The New Yorker
